Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

HS-10506

Phase 3Small molecule

Jiangsu Hansoh Pharmaceutical Co., Ltd.

1

Indications

3

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insomnia DisorderNot yet recruiting

Insomnia DisorderPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q2 2029

Phase 3Not yet recruiting

Insomnia Disorder

NCT07677384

Clinical

Trials by Indication[1]

Phase 11 trial

Phase 1a Study in Healthy Participants

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1·NCT05953506·52 enrolled

Insomnia1 trial

Phase Ⅰb/Ⅱ Study of HS-10506 in Chinese Participants With Insomnia Disorder

Unknown status· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 1/2·NCT06279286·312 enrolled

Insomnia Disorder1 trial

A Multicenter, Open-label, Phase 3 Study to Evaluate the Short-term and Long-term Safety of HS-10506 in Chinese Adult Patients With Insomnia Disorder

Not yet recruiting· Jiangsu Hansoh Pharmaceutical Co., Ltd. logo

Jiangsu Hansoh Pharmaceutical Co., Ltd.·Phase 3·NCT07677384·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HS-10506. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HS-10506 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HS-10506. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Jiangsu Hansoh Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Jiangsu Hansoh Pharmaceutical Co., Ltd.

Related News